185 related articles for article (PubMed ID: 30044154)
1. Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin.
Bae HD; Kim M; Lee J; Lee K
Drug Deliv; 2018 Nov; 25(1):1579-1584. PubMed ID: 30044154
[TBL] [Abstract][Full Text] [Related]
2. On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs.
Bae HD; Lee K
J Control Release; 2013 Sep; 170(3):358-64. PubMed ID: 23791976
[TBL] [Abstract][Full Text] [Related]
3. Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin.
Bae HD; Lee J; Jun KY; Kwon Y; Lee K
Drug Deliv; 2018 Nov; 25(1):1025-1032. PubMed ID: 29688087
[TBL] [Abstract][Full Text] [Related]
4. Potential of Translationally Controlled Tumor Protein-Derived Protein Transduction Domains as Antigen Carriers for Nasal Vaccine Delivery.
Bae HD; Lee J; Jin XH; Lee K
Mol Pharm; 2016 Sep; 13(9):3196-205. PubMed ID: 27454469
[TBL] [Abstract][Full Text] [Related]
5. Protein transduction domain of translationally controlled tumor protein: characterization and application in drug delivery.
Maeng J; Lee K
Drug Deliv; 2022 Dec; 29(1):3009-3021. PubMed ID: 36104954
[TBL] [Abstract][Full Text] [Related]
6. Optimization of formulation for enhanced intranasal delivery of insulin with translationally controlled tumor protein-derived protein transduction domain.
Bae HD; Lee JS; Pyun H; Kim M; Lee K
Drug Deliv; 2019 Dec; 26(1):622-628. PubMed ID: 31210056
[TBL] [Abstract][Full Text] [Related]
7. Transduction of translationally controlled tumor protein employing TCTP-derived protein transduction domain.
Maeng J; Kim HY; Shin DH; Lee K
Anal Biochem; 2013 Apr; 435(1):47-53. PubMed ID: 23256924
[TBL] [Abstract][Full Text] [Related]
8. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
Ahn S; Lee IH; Lee E; Kim H; Kim YC; Jon S
J Control Release; 2013 Sep; 170(2):226-32. PubMed ID: 23747732
[TBL] [Abstract][Full Text] [Related]
9. Cellular uptake mechanism of TCTP-PTD in human lung carcinoma cells.
Kim HY; Kim S; Pyun HJ; Maeng J; Lee K
Mol Pharm; 2015 Jan; 12(1):194-203. PubMed ID: 25423047
[TBL] [Abstract][Full Text] [Related]
10. Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction.
Kamei N; Okada N; Ikeda T; Choi H; Fujiwara Y; Okumura H; Takeda-Morishita M
Sci Rep; 2018 Dec; 8(1):17641. PubMed ID: 30518944
[TBL] [Abstract][Full Text] [Related]
11. Design and evaluation of variants of the protein transduction domain originated from translationally controlled tumor protein.
Kim M; Maeng J; Jung J; Kim HY; Kim HJ; Kwon Y; Lee K
Eur J Pharm Sci; 2011 May; 43(1-2):25-31. PubMed ID: 21440624
[TBL] [Abstract][Full Text] [Related]
12. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats.
Khafagy el-S; Kamei N; Nielsen EJ; Nishio R; Takeda-Morishita M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):736-43. PubMed ID: 24060698
[TBL] [Abstract][Full Text] [Related]
13. A protein transduction domain located at the NH2-terminus of human translationally controlled tumor protein for delivery of active molecules to cells.
Kim M; Kim M; Kim HY; Kim S; Jung J; Maeng J; Chang J; Lee K
Biomaterials; 2011 Jan; 32(1):222-30. PubMed ID: 20863558
[TBL] [Abstract][Full Text] [Related]
14. Effects of protein transduction domain (PTD) selection and position for improved intracellular delivery of PTD-Hsp27 fusion protein formulations.
Ul Ain Q; Lee JH; Woo YS; Kim YH
Arch Pharm Res; 2016 Sep; 39(9):1266-74. PubMed ID: 27381220
[TBL] [Abstract][Full Text] [Related]
15. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action.
Henkin RI
Nutrition; 2010 Jan; 26(1):33-9. PubMed ID: 20005465
[TBL] [Abstract][Full Text] [Related]
16. Systemic and brain delivery of antidiabetic peptides through nasal administration using cell-penetrating peptides.
Maeng J; Lee K
Front Pharmacol; 2022; 13():1068495. PubMed ID: 36452220
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.
Kim TH; Park CW; Kim HY; Chi MH; Lee SK; Song YM; Jiang HH; Lim SM; Youn YS; Lee KC
Biol Pharm Bull; 2012; 35(7):1076-83. PubMed ID: 22791155
[TBL] [Abstract][Full Text] [Related]
18. The cell penetrating ability of the proapoptotic peptide, KLAKLAKKLAKLAK fused to the N-terminal protein transduction domain of translationally controlled tumor protein, MIIYRDLISH.
Kim HY; Kim S; Youn H; Chung JK; Shin DH; Lee K
Biomaterials; 2011 Aug; 32(22):5262-8. PubMed ID: 21565400
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
Chuang EY; Nguyen GT; Su FY; Lin KJ; Chen CT; Mi FL; Yen TC; Juang JH; Sung HW
Biomaterials; 2013 Oct; 34(32):7994-8001. PubMed ID: 23891516
[TBL] [Abstract][Full Text] [Related]
20. Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
Tomono T; Yagi H; Ukawa M; Ishizaki S; Miwa T; Nonomura M; Igi R; Kumagai H; Miyata K; Tobita E; Kobayashi H; Sakuma S
Eur J Pharm Biopharm; 2020 Sep; 154():186-194. PubMed ID: 32681963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
